Group items tagged

A new report commissioned by the National Pharmacy Association (NPA) has revealed harsh financial realities faced by community pharmacies in England. The report by Professor David Taylor of University College London warned that 1000s of community pharmacy closure might take place by 2024 in England if the sector was not supported with additional funds. At the launch of the report titled 'Protecting UK Public Interests in NHS Community Pharmacy', Prof Taylor said: "There will be several 1,000s of closures over the next few years unless we take appropriate action, which doesn't mean to pour money all over it, but it is to fund appropriately when necessary. "At the moment, if we got a partial collapse in the pharmacy network it would disrupt medicine supply and increase health inequalities… For me, it's missing out on the future development of better and more accessible care, which would be the tragedy of reducing, harming and damaging the pharmacy network unnecessarily."

The General Pharmaceutical Council (GPhC) has published new reports on racism and other inequalities in pharmacy, following a series of virtual equality roundtables. This council organised its second equality roundtable on 18 September 2023, focussing on the topic of 'Language Barriers and Health Inequalities', and a follow-up roundtable on 'Racism in Pharmacy: Accountability Counts' on 10 October 2023. A wide range of pharmacy-related organisations, patient groups, equality groups, providers of translation services and software, individual pharmacists, pharmacy technicians and wider teams from different sectors and settings attended the events. GPhC chair, Gisela Abbam thanked speakers and attendees for listening and contributing to the important discussions around racism and language barriers, which she said are "not purely a pharmacy problem, nor a health problem", but a "much broader" system problem. "It is important we acknowledge that, and do what we can to tackle racism and barriers wherever we find them," she added.

Pharmacists from BAME backgrounds still face higher levels of discrimination, harassment, bullying, and career obstacles compared to their white counterparts, the Pharmacy Workforce Race Equality Standard (PWRES) report has revealed. Published by NHSE England, this report underscores the persistent presence of inequality, emphasising the crucial need for all stakeholders in the pharmacy sector to prioritise addressing these issues. The PWRES report indicates that pharmacy team members of Black ethnic backgrounds are less likely to perceive equal opportunities for career advancement or promotion within their trust. Additionally, female pharmacy team members from BAME backgrounds report higher incidents of personal discrimination in the workplace. The report also highlights an overrepresentation of pharmacy technicians from BAME backgrounds in lower-paid roles. "It is shocking and unacceptable to see that across all indicators the BME staff experience is worse than their white counterparts," said Tase Oputu, Chair of RPS in England.

NHS England and NHS Improvement published on May 26 the findings of the Fuller 'stocktake' - setting out how primary care can work with partners across health and care to best meet the needs of their local communities. Dr Claire Fuller's report lays emphasis on the essential role of primary care and the potential of integrated neighbourhood teams in reducing the burden of ill health and tackling health inequities. It commends community pharmacy for keeping "its doors open to the public throughout" the pandemic whilst being "among the most recognisable of a multitude of dedicated staff delivering care around the clock in every neighbourhood in the country". The report highlights "recruitment and retention challenges across the wider primary care workforce" including in community pharmacy. Stressing the importance of community pharmacy teams in urgent care and prevention, including early diagnosis of cancers, the report points out that pharmacists could play "a more active role in signposting eligible people to screening and supporting early diagnosis, building on a number of successful pilots such as those from the Accelerate, Coordinate, Evaluate (ACE) programme".

Royal Pharmaceutical Society in England and the Royal College of General Practitioners have published recommendations for the roll-out and success of the GP Community Pharmacist Consultation Service (GP CPCS). These recommendations follow a workshop with stakeholders from pharmacy, general practice and representative bodies, examining ways to maximise the potential of the service and meet growing demand on the health service. The workshop report made five recommendations: The NHS England and Improvement should provide additional investment in local system support and resources to drive the CPCS implementation and uptake between general practice and community pharmacy. National representative bodies should work with NHS E&I to develop national and local engagement and streamline communication plans for CPCS referral pathway. Focus on expanding the role of community pharmacists in the management of minor illness. Evaluation of CPCS service and its impacts on general practice workload, patient outcomes and health inequalities.

The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the collaboration between industry and the NHS to improve patient outcomes across the UK. Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these areas continues to be below the average of similar countries in Europe. The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations and industry have helped to tackle unwarranted variation in the uptake of innovative medicines. Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment. The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.